ESR1 and breast carcinoma: In the carcinogen-initiated, ER+ mammary tumor model we used at least 50% respond to TAM (Hilakivi-Clarke et al. 2017, Zhang et al. 2017); thus, tumor responses in this model mimic those seen in ER+ breast cancer patients.